Santhera Financial Statements From 2010 to 2025
| SANN Stock | CHF 15.00 0.04 0.27% |
Check Santhera Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Santhera Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Santhera financial statements analysis is a perfect complement when working with Santhera Pharmaceuticals Valuation or Volatility modules.
Santhera |
Santhera Pharmaceuticals Holding Company Return On Equity Analysis
Santhera Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Santhera Pharmaceuticals Return On Equity | -13.16 |
Most of Santhera Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Santhera Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Santhera Pharmaceuticals Holding has a Return On Equity of -13.1615. This is 45.09% lower than that of the Healthcare sector and 63.9% lower than that of the Biotechnology industry. The return on equity for all Switzerland stocks is notably higher than that of the company.
Santhera Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Santhera Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Santhera Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Santhera Pharmaceuticals competition to find correlations between indicators driving Santhera Pharmaceuticals's intrinsic value. More Info.Santhera Pharmaceuticals Holding is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Santhera Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Santhera Pharmaceuticals Financial Statements
Santhera Pharmaceuticals investors use historical fundamental indicators, such as Santhera Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Santhera Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. SANTHERA N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 114 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.